Imatinib treatment for locally advanced or metastatic dermatofibrosarcoma protuberans: A systematic review Review
| Authors: | Navarrete-Dechent, C.; Mori, S.; Barker, C. A.; Dickson, M. A.; Nehal, K. S. |
| Review Title: | Imatinib treatment for locally advanced or metastatic dermatofibrosarcoma protuberans: A systematic review |
| Abstract: | Importance: Dermatofibrosarcoma protuberans (DFSP) has the potential for local destruction and recurrence, although it carries a low risk of metastasis. Complete surgical resection with negative margins is considered the gold standard for treatment; however, there are cases that are unresectable owing to tumor extension or size or owing to risk of cosmetic and/or functional impairment. Imatinib treatment has been used for locally advanced or metastatic DFSP. Objective: To evaluate the usefulness of imatinib for treating DFSP. Evidence Review: We conducted a systematic review on the PubMed and Embase databases for articles published from September 2002 through October 2017 using the key words "dermatofibrosarcoma" or "dermatofibrosarcoma protuberans" AND "therapy" AND "imatinib." References within retrieved articles were also reviewed to identify additional studies. Studies of adults with histologically proven DFSP treated with imatinib as monotherapy or as an adjuvant or neoadjuvant therapy to surgery were included. Extracted data were analyzed using descriptive statistics. PRISMA guidelines were followed. All analysis took place October through December 2017. Findings: Nine studies met inclusion criteria; 152 patients were included. The calculated mean patient age was 49.3 years (range, 20-73 years). Calculated mean tumor diameter was 9.9 cm (range, 1.2-49.0 cm). When COL1A1-PDGFβ protein translocation (collagen, type 1, alpha 1-platelet-derived growth factor β) was reported, it was present in 90.9% of patients (111 of 122). Complete response was seen in 5.2% of patients (8 of 152), partial response in 55.2% (84 of 152), stable disease in 27.6% (42 of 152), and progression in 9.2% (14 of 152). Four of the 152 patients (2.6%) were excluded from the analysis owing to unknown or unevaluable response. There were no differences in response rate using 400-mg or 800-mg daily doses (67.5% or 27 of 40 patients for 400-mg dose vs 67.1% or 49 of 73 patients for 800-mg dose complete or partial response; P >.99). Adverse events were present in at least 73.5% of cases (78 of 106); severe adverse events were present in 15.1% of cases (20 of 132). Conclusions and Relevance: Imatinib is a useful directed therapy in patients with DFSP who are not surgical candidates owing to disease extension or significant cosmetic or functional impairment. There seems to be no difference between 400- or 800-mg daily doses. © 2019 American Medical Association. All rights reserved. |
| Journal Title: | JAMA Dermatology |
| Volume: | 155 |
| Issue: | 3 |
| ISSN: | 2168-6068 |
| Publisher: | American Medical Association |
| Date Published: | 2019-03-01 |
| Start Page: | 361 |
| End Page: | 369 |
| Language: | English |
| DOI: | 10.1001/jamadermatol.2018.4940 |
| PROVIDER: | scopus |
| PUBMED: | 30601909 |
| DOI/URL: | |
| Notes: | Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
278Nehal -
218Barker -
170Dickson -
73Navarrete -
16Mori-DeMarco
Related MSK Work